Eribulin (mesylate)
Eribulin (E7389) mesylate is a microtubule targeting agent that is used for the research of metastatic breast cancer. Eribulin mesylate inhibits the proliferation of cancer cells by binding microtubule proteins and microtubules.
Product Specifications
CAS Number
441045-17-6
Product Name Alternative
B1939 (mesylate) ; E7389 (mesylate) ; ER-086526 (mesylate)
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Apoptosis; Microtubule/Tubulin
Type
Reference compound
Related Pathways
Apoptosis; Cell Cycle/DNA Damage; Cytoskeleton
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/eribulin-mesylate.html
Purity
99.91
Solubility
DMSO : ≥ 100 mg/mL
Smiles
C=C1C[C@@](CC[C@@]2(C[C@@]3([H])O4)O[C@]([C@](O[C@](C5)([H])CC6)([H])[C@@]6([H])O7)([H])[C@@]4([H])[C@]7([H])[C@@]3([H])O2)([H])O[C@@]1([H])CC[C@](C[C@@H](C)C8=C)([H])O[C@]8([H])C[C@@](O[C@H](C[C@H](O)CN)[C@@H]9OC)([H])[C@]9([H])CC5=O.CS(=O)(O)=O
Molecular Formula
C41H63NO14S
Molecular Weight
826.00
Precautions
H302, H315, H319, H335
References & Citations
[1]Okouneva, T., et al., Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase. Mol Cancer Ther, 2008. 7 (7) : p. 2003-11.|[2]Smith, J.A., et al., Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability. Biochemistry, 2010. 49 (6) : p. 1331-7.|[3]Towle, M.J., et al., Eribulin induces irreversible mitotic blockade: implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions. Cancer Res, 2011. 71 (2) : p. 496-505.|[4]Watanabe K, et, al. Low-dose eribulin reduces lung metastasis of osteosarcoma in vitro and in vivo. Oncotarget. 2019 Jan 4; 10 (2) : 161-174.
Shipping Conditions
Dry Ice
Storage Conditions
-80°C, protect from light, stored under nitrogen
Scientific Category
Reference compound1
Clinical Information
Launched
Citation 01
Cell Rep Med. 2025 Apr 2:102053.|mBio. 2025 Aug 15:e0048425.|Molecules. 2025 Feb 14;30 (4) :895.|Dev Cell. 2025 Mar 25:S1534-5807 (25) 00151-0.|iScience. 2022 Sep 6;25 (10) :105081.|J Control Release. 2025 Oct 14;388 (Pt 1) :114325.|NPJ Breast Cancer. 2025 Feb 17;11 (1) :17.|Res Sq. 2024 Sep 17.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC400204-100 1x 100 µL
Complement C4d (C4D204), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
TA384556 100 µL
Integrin alpha 5 (ITGA5) Rabbit Polyclonal Antibody
Sign In for Pricing
View Details 